A flexible futility monitoring method with time-varying conditional power boundary

Background In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy...

Full description

Saved in:
Bibliographic Details
Published inClinical trials (London, England) Vol. 7; no. 3; pp. 209 - 218
Main Authors Ying Zhang, Clarke, William R
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.06.2010
Sage Publications Ltd
Subjects
Online AccessGet full text
ISSN1740-7745
1740-7753
1740-7753
DOI10.1177/1740774510369686

Cover

Loading…
Abstract Background In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy or futility. Conditional power is used as the decision rule for the DSMB to recommend stopping the trial for futility. An aggressive rule for futility stopping sets a relatively high threshold for the conditional power which may result in significant loss of overall power of the study. A conservative rule using a lower threshold may not be able to stop the trial early when there is indeed no treatment efficacy. Purpose The goal of this article is to develop a flexible futility monitoring plan with a time-varying conditional power boundary that maintains the overall power of the study well, but has a better chance to stop the trial earlier for futility compared to a futility stopping rule with a fixed value for the minimum conditional power to continue. Methods The conditional power boundary for futility is developed using the β-spending function method for sequential test statistics and assuming no interim analysis for efficacy. It is then modified to account for the repeated interim analyses for efficacy. Results Simulation studies that mirror the design of the COSS trial show that the proposed method with sample size calculated without considering interim analyses will maintain the designed size and power well when the designed effect size holds, but will have a better chance to exit the trial earlier if the true effect size is smaller than the designed size such that it is not clinically meaningful to conduct the trial. Limitations The method is valid for sequential test statistics that constitute of a stochastic process which approximates the Brownian motion. It is not applicable to the monitored process that behaves quire differently from the Brownian motion. Conclusions The proposed conditional power method facilitates a flexible futility monitoring plan that can be easily implemented in long-term clinical trials where multiple interim analyses are required. It provides the DSMB an objective guideline to use in considering early stopping for futility. Clinical Trials 2010; 7: 209. http:// ctj.sagepub.com
AbstractList In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy or futility. Conditional power is used as the decision rule for the DSMB to recommend stopping the trial for futility. An aggressive rule for futility stopping sets a relatively high threshold for the conditional power which may result in significant loss of overall power of the study. A conservative rule using a lower threshold may not be able to stop the trial early when there is indeed no treatment efficacy.BACKGROUNDIn an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy or futility. Conditional power is used as the decision rule for the DSMB to recommend stopping the trial for futility. An aggressive rule for futility stopping sets a relatively high threshold for the conditional power which may result in significant loss of overall power of the study. A conservative rule using a lower threshold may not be able to stop the trial early when there is indeed no treatment efficacy.The goal of this article is to develop a flexible futility monitoring plan with a time-varying conditional power boundary that maintains the overall power of the study well, but has a better chance to stop the trial earlier for futility compared to a futility stopping rule with a fixed value for the minimum conditional power to continue.PURPOSEThe goal of this article is to develop a flexible futility monitoring plan with a time-varying conditional power boundary that maintains the overall power of the study well, but has a better chance to stop the trial earlier for futility compared to a futility stopping rule with a fixed value for the minimum conditional power to continue.The conditional power boundary for futility is developed using the beta-spending function method for sequential test statistics and assuming no interim analysis for efficacy. It is then modified to account for the repeated interim analyses for efficacy.METHODSThe conditional power boundary for futility is developed using the beta-spending function method for sequential test statistics and assuming no interim analysis for efficacy. It is then modified to account for the repeated interim analyses for efficacy.Simulation studies that mirror the design of the COSS trial show that the proposed method with sample size calculated without considering interim analyses will maintain the designed size and power well when the designed effect size holds, but will have a better chance to exit the trial earlier if the true effect size is smaller than the designed size such that it is not clinically meaningful to conduct the trial.RESULTSSimulation studies that mirror the design of the COSS trial show that the proposed method with sample size calculated without considering interim analyses will maintain the designed size and power well when the designed effect size holds, but will have a better chance to exit the trial earlier if the true effect size is smaller than the designed size such that it is not clinically meaningful to conduct the trial.The method is valid for sequential test statistics that constitute of a stochastic process which approximates the Brownian motion. It is not applicable to the monitored process that behaves quire differently from the Brownian motion.LIMITATIONSThe method is valid for sequential test statistics that constitute of a stochastic process which approximates the Brownian motion. It is not applicable to the monitored process that behaves quire differently from the Brownian motion.The proposed conditional power method facilitates a flexible futility monitoring plan that can be easily implemented in long-term clinical trials where multiple interim analyses are required. It provides the DSMB an objective guideline to use in considering early stopping for futility. Clinical Trials 2010; 7: 209. http:// ctj.sagepub.com.CONCLUSIONSThe proposed conditional power method facilitates a flexible futility monitoring plan that can be easily implemented in long-term clinical trials where multiple interim analyses are required. It provides the DSMB an objective guideline to use in considering early stopping for futility. Clinical Trials 2010; 7: 209. http:// ctj.sagepub.com.
Background In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy or futility. Conditional power is used as the decision rule for the DSMB to recommend stopping the trial for futility. An aggressive rule for futility stopping sets a relatively high threshold for the conditional power which may result in significant loss of overall power of the study. A conservative rule using a lower threshold may not be able to stop the trial early when there is indeed no treatment efficacy. Purpose The goal of this article is to develop a flexible futility monitoring plan with a time-varying conditional power boundary that maintains the overall power of the study well, but has a better chance to stop the trial earlier for futility compared to a futility stopping rule with a fixed value for the minimum conditional power to continue. Methods The conditional power boundary for futility is developed using the β-spending function method for sequential test statistics and assuming no interim analysis for efficacy. It is then modified to account for the repeated interim analyses for efficacy. Results Simulation studies that mirror the design of the COSS trial show that the proposed method with sample size calculated without considering interim analyses will maintain the designed size and power well when the designed effect size holds, but will have a better chance to exit the trial earlier if the true effect size is smaller than the designed size such that it is not clinically meaningful to conduct the trial. Limitations The method is valid for sequential test statistics that constitute of a stochastic process which approximates the Brownian motion. It is not applicable to the monitored process that behaves quire differently from the Brownian motion. Conclusions The proposed conditional power method facilitates a flexible futility monitoring plan that can be easily implemented in long-term clinical trials where multiple interim analyses are required. It provides the DSMB an objective guideline to use in considering early stopping for futility. Clinical Trials 2010; 7: 209. http:// ctj.sagepub.com
In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy or futility. Conditional power is used as the decision rule for the DSMB to recommend stopping the trial for futility. An aggressive rule for futility stopping sets a relatively high threshold for the conditional power which may result in significant loss of overall power of the study. A conservative rule using a lower threshold may not be able to stop the trial early when there is indeed no treatment efficacy. The goal of this article is to develop a flexible futility monitoring plan with a time-varying conditional power boundary that maintains the overall power of the study well, but has a better chance to stop the trial earlier for futility compared to a futility stopping rule with a fixed value for the minimum conditional power to continue. The conditional power boundary for futility is developed using the beta-spending function method for sequential test statistics and assuming no interim analysis for efficacy. It is then modified to account for the repeated interim analyses for efficacy. Simulation studies that mirror the design of the COSS trial show that the proposed method with sample size calculated without considering interim analyses will maintain the designed size and power well when the designed effect size holds, but will have a better chance to exit the trial earlier if the true effect size is smaller than the designed size such that it is not clinically meaningful to conduct the trial. The method is valid for sequential test statistics that constitute of a stochastic process which approximates the Brownian motion. It is not applicable to the monitored process that behaves quire differently from the Brownian motion. The proposed conditional power method facilitates a flexible futility monitoring plan that can be easily implemented in long-term clinical trials where multiple interim analyses are required. It provides the DSMB an objective guideline to use in considering early stopping for futility. Clinical Trials 2010; 7: 209. http:// ctj.sagepub.com.
Background: In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim analyses whose results will be reviewed by an independent DSMB to determine if the trial needs to be stopped early due to either efficacy or futility. Conditional power is used as the decision rule for the DSMB to recommend stopping the trial for futility. An aggressive rule for futility stopping sets a relatively high threshold for the conditional power which may result in significant loss of overall power of the study. A conservative rule using a lower threshold may not be able to stop the trial early when there is indeed no treatment efficacy. Purpose: The goal of this article is to develop a flexible futility monitoring plan with a time-varying conditional power boundary that maintains the overall power of the study well, but has a better chance to stop the trial earlier for futility compared to a futility stopping rule with a fixed value for the minimum conditional power to continue. Methods: The conditional power boundary for futility is developed using the β-spending function method for sequential test statistics and assuming no interim analysis for efficacy. It is then modified to account for the repeated interim analyses for efficacy. Results: Simulation studies that mirror the design of the COSS trial show that the proposed method with sample size calculated without considering interim analyses will maintain the designed size and power well when the designed effect size holds, but will have a better chance to exit the trial earlier if the true effect size is smaller than the designed size such that it is not clinically meaningful to conduct the trial. Limitations: The method is valid for sequential test statistics that constitute of a stochastic process which approximates the Brownian motion. It is not applicable to the monitored process that behaves quire differently from the Brownian motion. Conclusions The proposed conditional power method facilitates a flexible futility monitoring plan that can be easily implemented in long-term clinical trials where multiple interim analyses are required. It provides the DSMB an objective guideline to use in considering early stopping for futility. [PUBLICATION ABSTRACT]
Author Ying Zhang
Clarke, William R
Author_xml – sequence: 1
  surname: Ying Zhang
  fullname: Ying Zhang
  organization: Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
– sequence: 2
  givenname: William R
  surname: Clarke
  fullname: Clarke, William R
  organization: Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20423927$$D View this record in MEDLINE/PubMed
BookMark eNp9UUlr3DAUFiWhWe89FZNLT2612bIugRC6QaAQkrOQrecZBVmaSHKWf18Nk60DzUkPfQvf-94B2vHBA0KfCP5KiBDfiOBYCN4QzFrZdu0HtL_-qoVo2M7LzJs9dJDSDca0azr2Ee1RzCmTVOyjy7NqdPBgewfVOGfrbH6spuBtDtH6RTVBXgZT3du8rLKdoL7T8XENDMEbm23w2lWrcA-x6sPsTUGP0O6oXYLjp_cQXf_4fnX-q7748_P3-dlFPfAW5xoGLZmgxHAhpGkM4ZSwjmvWYdYBZkY0cuypMLzjhPa6Hc3Qt4SBHA3ty4KH6HTju5r7CcwAPkft1CraqaRQQVv1L-LtUi3CnZKlrVbgYvDlySCG2xlSVpNNAzinPYQ5KcFYwyXFXWGebDFvwhzL6klRiqkoe8hC-vw2z0uQ57ILod0QhhhSijCqwWa97rDEs04RrNZXVdtXLUK8JXz2fkdSbyRJL-A17X_5fwFAwbCn
CitedBy_id crossref_primary_10_1002_bimj_202300094
crossref_primary_10_3390_math10203898
crossref_primary_10_1080_03610926_2014_919400
crossref_primary_10_1080_03610926_2024_2447827
crossref_primary_10_1177_17407745231181908
crossref_primary_10_1080_10543406_2014_932285
crossref_primary_10_1080_19466315_2017_1340906
crossref_primary_10_1080_07474946_2021_2010411
crossref_primary_10_1002_bimj_201100128
Cites_doi 10.1093/biomet/70.3.659
10.1016/S0197-2456(02)00218-0
10.2307/2531692
10.1016/0378-3758(94)90187-2
10.1002/pst.93
10.2307/2531870
10.1002/sim.4780120804
10.1016/S0197-2456(00)00057-X
10.1093/biomet/69.3.661
10.1093/biomet/67.3.651
ContentType Journal Article
Copyright The Author(s), 2010.
SAGE Publications © Jun 2010
Copyright_xml – notice: The Author(s), 2010.
– notice: SAGE Publications © Jun 2010
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TK
7TS
7U7
7X7
7XB
88E
8C1
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AN0
AZQEC
BENPR
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
KB0
M0S
M1P
M2O
MBDVC
NAPCQ
PADUT
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.1177/1740774510369686
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
Physical Education Index
Toxicology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
Nursing & Allied Health Premium
Research Library China
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
Physical Education Index
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
Research Library China
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Central Basic
Toxicology Abstracts
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE

Research Library Prep
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1740-7753
EndPage 218
ExternalDocumentID PMC9036670
2037695831
20423927
10_1177_1740774510369686
10.1177_1740774510369686
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: 5U01NS041895
– fundername: NINDS NIH HHS
  grantid: U01 NS041895
GroupedDBID ---
-TM
.2E
.2J
.2N
01A
04C
0R~
1~K
29B
31R
31U
31X
31Z
36B
4.4
53G
54M
5GY
5RE
5VS
6PF
7RV
7X7
88E
8C1
8FI
8FJ
8G5
8R4
8R5
AABMB
AACMV
AACTG
AADUE
AAEWN
AAGLT
AAGMC
AAJPV
AAKGS
AAQDB
AAQXI
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAWTL
ABAWP
ABCCA
ABCJG
ABEIX
ABFWQ
ABHQH
ABIDT
ABJIS
ABJZC
ABKRH
ABLUO
ABPNF
ABQXT
ABRHV
ABTDE
ABUJY
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACFEJ
ACGFS
ACGZU
ACJER
ACJTF
ACLFY
ACLZU
ACOFE
ACOXC
ACPRK
ACROE
ACRPL
ACSIQ
ACUAV
ACUIR
ACXKE
ACXMB
ADBBV
ADDLC
ADEBD
ADNMO
ADNON
ADRRZ
ADVBO
ADYCS
ADZZY
AECGH
AEDTQ
AEIJN
AEKYL
AENEX
AEPTA
AEQLS
AERKM
AESZF
AEUHG
AEWDL
AEWHI
AEXNY
AFEET
AFKRA
AFKRG
AFMOU
AFQAA
AFRAH
AFUIA
AFWMB
AGHKR
AGKLV
AGNHF
AGPXR
AGQPQ
AGWFA
AGWNL
AHDMH
AHHFK
AHMBA
AIIQI
AJUZI
AJXAJ
ALIPV
ALKWR
ALMA_UNASSIGNED_HOLDINGS
AMCVQ
AN0
ANDLU
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
AZQEC
B3H
B8M
B8R
B8Z
B94
BBRGL
BDDNI
BENPR
BKEYQ
BKIIM
BKSCU
BMSDO
BNQBC
BPACV
BPHCQ
BSEHC
BVXVI
BWJAD
CAG
CCPQU
CDWPY
CFDXU
COF
CS3
DB0
DC-
DC.
DF0
DO-
DOPDO
DU5
DV7
DV9
DWQXO
EBD
EBS
EIHBH
EJD
EMB
EMOBN
EX3
F5P
FEDTE
FHBDP
FYUFA
GNUQQ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GUQSH
H13
HF~
HMCUK
HVGLF
HZ~
J8X
K.F
M1P
M2O
N9A
NAPCQ
O9-
P.B
P2P
PADUT
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
Q7L
Q7U
Q83
ROL
S01
SASJQ
SAUOL
SCNPE
SDB
SFC
SFK
SFT
SGO
SGR
SGV
SGZ
SHG
SNB
SPJ
SPQ
SPV
STM
SV3
UDS
UKHRP
WOW
YHZ
ZGI
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
AJGYC
CITATION
ALTZF
CGR
CUY
CVF
ECM
EIF
M4V
NPM
3V.
7TK
7TS
7U7
7XB
8FK
AAPII
AJVBE
C1K
K9.
MBDVC
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
Q9U
7X8
5PM
AJHME
ID FETCH-LOGICAL-c460t-eca93721d4779d5d1421384a38038e03d759fb27d48412ba6fdcb613e9fd2b753
IEDL.DBID 7X7
ISSN 1740-7745
1740-7753
IngestDate Thu Aug 21 13:39:00 EDT 2025
Mon Jul 21 11:50:21 EDT 2025
Sat Jul 26 02:22:47 EDT 2025
Thu Apr 03 07:02:33 EDT 2025
Tue Jul 01 05:27:38 EDT 2025
Thu Apr 24 23:08:07 EDT 2025
Tue Jun 17 22:28:24 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License https://journals.sagepub.com/page/policies/text-and-data-mining-license
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-eca93721d4779d5d1421384a38038e03d759fb27d48412ba6fdcb613e9fd2b753
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/9036670
PMID 20423927
PQID 220273729
PQPubID 40366
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9036670
proquest_miscellaneous_733549208
proquest_journals_220273729
pubmed_primary_20423927
crossref_citationtrail_10_1177_1740774510369686
crossref_primary_10_1177_1740774510369686
sage_journals_10_1177_1740774510369686
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-06-01
PublicationDateYYYYMMDD 2010-06-01
PublicationDate_xml – month: 06
  year: 2010
  text: 2010-06-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
PublicationTitle Clinical trials (London, England)
PublicationTitleAlternate Clin Trials
PublicationYear 2010
Publisher SAGE Publications
Sage Publications Ltd
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
References Emerson SS, Fleming TR 1989; 45
Freidlin B., Korn EL 2002; 23
Lan KKG, Zucker DM 1993; 12
DeMets DL, Ware JH 1982; 69
Lan KKG, DeMets DL 1983; 70
Lan KKG, Simon R., Halperin M. 1982; 11
Pampallona SK, Tsiatis AA 1994; 42
Reboussin DM, DeMets DL, Kim KM 2000; 21
DeMets DL, Ware JH 1980; 67
Chang WH, Chuang-Stein C. 2004; 3
Lan KKG, Witts J. 1988; 44
Lan KKG (atypb9) 1982; 11
atypb11
atypb12
atypb1
atypb3
atypb2
atypb10
atypb5
atypb4
atypb7
Jennison C. (atypb8) 2000
atypb6
References_xml – volume: 67
  start-page: 651
  year: 1980
  end-page: 60
  article-title: Group sequential methods for clinical trials with one-sided hypothesis
  publication-title: Biometrika
– volume: 21
  start-page: 190
  year: 2000
  end-page: 207
  article-title: Computations for group sequential boundaries using the Lan-DeMets spending function method
  publication-title: Control Clin Trials
– volume: 3
  start-page: 51
  year: 2004
  end-page: 9
  article-title: Type I error and power in trials with one interim futility analysis
  publication-title: Pharm Stat
– volume: 69
  start-page: 661
  year: 1982
  end-page: 3
  article-title: Asymmetric group sequential boundaries for monitoring clinical trial
  publication-title: Biometrika
– volume: 45
  start-page: 905
  year: 1989
  end-page: 23
  article-title: Symmetric group sequential test designs
  publication-title: Biometrics
– volume: 12
  start-page: 753
  year: 1993
  end-page: 65
  article-title: Sequential monitoring of clinical trials: the role of information and Brownian motion
  publication-title: Stat Med
– volume: 23
  start-page: 355
  year: 2002
  end-page: 66
  article-title: A comment on futility monitoring
  publication-title: Control Clin Trials
– volume: 42
  start-page: 19
  year: 1994
  end-page: 35
  article-title: Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis
  publication-title: J Stat Plan Infer
– volume: 44
  start-page: 579
  year: 1988
  end-page: 85
  article-title: The B-value: a tool for monitoring data
  publication-title: Biometrics
– volume: 70
  start-page: 659
  year: 1983
  end-page: 63
  article-title: Discrete sequential boundaries for clinical trials
  publication-title: Biometrika
– volume: 11
  start-page: 207
  year: 1982
  end-page: 19
  article-title: Stochastically curtailed tests in long-term clinical trials
  publication-title: Commun Stat
– ident: atypb1
  doi: 10.1093/biomet/70.3.659
– ident: atypb6
  doi: 10.1016/S0197-2456(02)00218-0
– ident: atypb4
  doi: 10.2307/2531692
– ident: atypb5
  doi: 10.1016/0378-3758(94)90187-2
– volume: 11
  start-page: 207
  year: 1982
  ident: atypb9
  publication-title: Commun Stat
– ident: atypb10
  doi: 10.1002/pst.93
– ident: atypb7
  doi: 10.2307/2531870
– ident: atypb11
  doi: 10.1002/sim.4780120804
– volume-title: Group Sequential Methods with Applications to Clinical Trials
  year: 2000
  ident: atypb8
– ident: atypb12
  doi: 10.1016/S0197-2456(00)00057-X
– ident: atypb3
  doi: 10.1093/biomet/69.3.661
– ident: atypb2
  doi: 10.1093/biomet/67.3.651
SSID ssj0028583
Score 1.9165651
Snippet Background In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple...
In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple interim...
Background: In an ongoing multi-center randomized control clinical trial, the Carotid Occlusion Surgery Study (COSS), the study protocol specifies multiple...
SourceID pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 209
SubjectTerms Algorithms
Carotid Artery Diseases - surgery
Carotid Artery Diseases - therapy
Clinical trials
Design of experiments
Endpoint Determination - methods
Humans
Medical Futility
Medical research
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Research Design
Research methodology
Stroke - prevention & control
Time Factors
Title A flexible futility monitoring method with time-varying conditional power boundary
URI https://journals.sagepub.com/doi/full/10.1177/1740774510369686
https://www.ncbi.nlm.nih.gov/pubmed/20423927
https://www.proquest.com/docview/220273729
https://www.proquest.com/docview/733549208
https://pubmed.ncbi.nlm.nih.gov/PMC9036670
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS-QwFD64I8i-iNe164U8iOBDmDZJm_ZJRlFEUEQU5q0kTcIK2hlnxoX995vTZjpe0Jc-pCkNOUnONd8HcOi8EaxFIanhzlFMrVHl5Uy9KnUql07o5n7F9U12-SCuhukw1OZMQ1nl_ExsDmozqjBG3mfopWOO6WT8QpE0CpOrgUHjBywjchn6XnK48LfytEHh9DZ37I1IkS6ylH1sw6YkRj47vEj9Vit9MjU_V0y-KftqNNHFGqwGE5IMWpmvw5KtN2DlOiTJN-FuQBzCXOonS5xfV2hok-dm72IQj7Sk0QQjsASp5elfNcHLTsS7xuaxjQ2SMbKnEd2QLk3-bcHDxfn92SUN1Am0Elk8o7ZS3u5giRFSFiY1iWAJz4XiecxzG3Mj08JpJo3IRcK0ypyptNfstnCGae_CbEOvHtV2B4hKKs2t4zJWyjubVcGYY0aZTCirBa8i6M-nrqwCrjjSWzyVSYAS_zjZERx3X4xbTI1v-u7OpVGG3TUtu7UQAene-m2BuQ5V29HrtJScI_ZcnEfwqxVd9yuGpUAFkxHId0LtOiDi9vs39eOfBnm78KPKZBzBEYp_MaCvRv_729Hvws-2FgFjOnvQm01e7b43cWb6oFnI_pmfJQewfHp-c3v3H3SA-Is
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB4hKhUuqC9oSml9aCtxsDaxnTg5VAjRot3CcqhA4hbs2FZXWrLbfbTiR_U_1pMXUNS9cbUdxfKMPeOZ8fcBfHDeCdYik9Rw5yim1qjycqbelDqVSid09b5ieJb0L8S3y_hyDf60b2GwrLI9E6uD2kwKjJH3GN7SMcd0MP1JkTQKk6stg0atFSf25re_sc0_D7548X5k7Pjr-VGfNqQCtBBJuKC2UN4is8gIKTMTm0iwiKdC8TTkqQ25kXHmNJNGpCJiWiXOFNrbPJs5w7REkgh_4j8RnEuE6k-PuooSlsYV6qf38UPvtIr4NivawzZsikLkz8OH23et4APX9mGF5p0ys8ryHT-DrcZlJYe1jj2HNVu-gKfDJin_Er4fEoewmnpsifN6jI49ua7OCgwakpqkmmDElyCVPf2lZvi4iviruBnVsUgyRbY2oiuSp9nNK7h4lFXdhvVyUtrXQFRUaG4dl6FS_nJbZIw5ZpRJhLJa8CKAXrt0edHgmCOdxjiPGujyfxc7gP3ui2mN4bFi7G4rjbzZzfO8070ASNfrtyHmVlRpJ8t5LjlHrLswDWCnFl33K4alRxmTAch7Qu0GIML3_Z5y9KNC-s78rBIZBvAJxX87of_N_s3K2b-Hjf758DQ_HZyd7MJmXQeB8aS3sL6YLe2ed68W-l2l1ASuHnsX_QVX4THw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+flexible+futility+monitoring+method+with+time-varying+conditional+power+boundary&rft.jtitle=Clinical+trials+%28London%2C+England%29&rft.au=Ying+Zhang&rft.au=Clarke%2C+William+R&rft.date=2010-06-01&rft.pub=SAGE+Publications&rft.issn=1740-7745&rft.volume=7&rft.issue=3&rft.spage=209&rft.epage=218&rft_id=info:doi/10.1177%2F1740774510369686&rft.externalDocID=10.1177_1740774510369686
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1740-7745&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1740-7745&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1740-7745&client=summon